Your browser is no longer supported. Please, upgrade your browser.
Settings
BEAM [NASD]
Beam Therapeutics Inc.
Index- P/E- EPS (ttm)-6.68 Insider Own1.70% Shs Outstand66.38M Perf Week-10.27%
Market Cap5.01B Forward P/E- EPS next Y-4.12 Insider Trans-17.44% Shs Float43.98M Perf Month-26.25%
Income-401.40M PEG- EPS next Q-1.06 Inst Own77.80% Short Float11.03% Perf Quarter-39.22%
Sales0.80M P/S6262.29 EPS this Y-108.70% Inst Trans0.00% Short Ratio7.92 Perf Half Y-19.47%
Book/sh12.86 P/B5.36 EPS next Y40.60% ROA-50.30% Target Price125.67 Perf Year14.77%
Cash/sh12.84 P/C5.37 EPS next 5Y2.70% ROE-77.60% 52W Range56.34 - 138.52 Perf YTD-15.57%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-50.24% Beta-
Dividend %- Quick Ratio9.30 Sales past 5Y- Gross Margin- 52W Low22.35% ATR5.83
Employees181 Current Ratio9.30 Sales Q/Q0.00% Oper. Margin- RSI (14)29.90 Volatility9.69% 7.28%
OptionableYes Debt/Eq0.01 EPS Q/Q38.40% Profit Margin- Rel Volume1.31 Prev Close68.02
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume612.06K Price68.93
Recom2.10 SMA20-18.99% SMA50-22.16% SMA200-22.90% Volume804,242 Change1.34%
Oct-19-21Initiated SVB Leerink Outperform $117
Sep-24-21Resumed Stifel Buy $85 → $120
Sep-10-21Initiated BofA Securities Buy $150
May-11-21Initiated Redburn Buy
May-04-21Initiated RBC Capital Mkts Sector Perform $85
Mar-01-21Downgrade Barclays Overweight → Equal Weight $47 → $90
Feb-16-21Initiated Wells Fargo Overweight $145
Jan-29-21Downgrade JP Morgan Overweight → Neutral $100
Jan-06-21Initiated Stifel Hold $84
Aug-05-20Initiated William Blair Outperform
Mar-02-20Initiated Wedbush Outperform $32
Mar-02-20Initiated JP Morgan Overweight $31
Mar-02-20Initiated Jefferies Buy $32
Mar-02-20Initiated Barclays Overweight $32
Dec-03-21 06:15AM  
Nov-12-21 07:00AM  
Nov-11-21 06:30AM  
Nov-09-21 01:41PM  
09:15AM  
Nov-08-21 07:15AM  
06:00AM  
06:00AM  
Nov-04-21 09:40AM  
Nov-02-21 03:02PM  
Oct-27-21 05:06AM  
Oct-26-21 05:55AM  
Oct-25-21 09:38AM  
Oct-20-21 06:23PM  
06:30AM  
Oct-19-21 03:55PM  
09:00AM  
06:30AM  
Oct-17-21 09:01AM  
Oct-15-21 09:57AM  
07:47AM  
Oct-12-21 02:27PM  
05:43AM  
Oct-04-21 05:55AM  
Oct-01-21 08:44AM  
Sep-28-21 06:30AM  
Sep-27-21 09:53AM  
06:30AM  
Sep-23-21 07:42AM  
06:30AM  
05:55AM  
Sep-12-21 07:57AM  
Sep-08-21 06:30AM  
Sep-03-21 07:30AM  
Aug-27-21 06:55AM  
Aug-21-21 07:20AM  
Aug-14-21 03:45AM  
Aug-11-21 09:40AM  
Aug-10-21 07:45AM  
06:30AM  
Aug-04-21 03:00PM  
Aug-03-21 06:30AM  
Jul-28-21 01:08PM  
Jul-27-21 10:38PM  
Jul-21-21 05:55AM  
Jul-16-21 11:02AM  
Jul-08-21 12:39PM  
06:30AM  
Jul-06-21 07:42AM  
Jul-02-21 12:48PM  
09:19AM  
Jun-30-21 04:15PM  
06:42AM  
Jun-28-21 02:36PM  
12:22PM  
09:44AM  
Jun-04-21 08:37AM  
May-26-21 11:00AM  
May-25-21 06:30AM  
May-24-21 05:52AM  
May-11-21 12:28PM  
12:16PM  
07:45AM  
06:30AM  
May-04-21 03:00PM  
Apr-30-21 01:31PM  
11:15AM  
Apr-27-21 04:41PM  
Apr-20-21 10:12AM  
Apr-17-21 06:01AM  
Mar-28-21 11:11PM  
Mar-15-21 06:30AM  
06:15AM  
Mar-04-21 06:30AM  
Feb-23-21 04:19PM  
01:49PM  
Feb-16-21 01:36PM  
08:12AM  
Feb-05-21 08:58AM  
Jan-19-21 06:30AM  
Jan-15-21 06:12PM  
Jan-14-21 03:11PM  
03:04PM  
Jan-11-21 06:30AM  
Jan-07-21 04:24PM  
Jan-06-21 11:00AM  
09:00AM  
Jan-05-21 06:30AM  
Dec-24-20 11:10AM  
Dec-10-20 10:02AM  
Dec-07-20 05:19PM  
Dec-05-20 07:00AM  
Nov-20-20 04:01PM  
Nov-13-20 08:00AM  
Nov-10-20 06:30AM  
Nov-09-20 08:15AM  
Nov-02-20 06:06AM  
Oct-07-20 10:04AM  
Oct-02-20 08:00AM  
Sep-28-20 04:18PM  
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia. It also develops therapies for alpha-1 antitrypsin deficiency and glycogen storage disorder 1a; and therapies for ocular and central nervous system disorders. The company has a strategic alliance with Boston Children's Hospital; a research and clinical collaboration agreement with Magenta Therapeutics, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration with Apellis Pharmaceuticals, Inc. to apply base editing technology for discovering new treatments for complement-driven diseases. Beam Therapeutics Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Evans John M.CEOOct 06Option Exercise1.0327,70028,5311,061,225Oct 08 04:21 PM
Evans John M.CEOOct 06Sale83.8020,0001,676,070183,000Oct 08 04:21 PM
Evans John M.CEOOct 06Sale83.8027,7002,321,1981,033,525Oct 08 04:21 PM
Ciaramella GiuseppePresident & CSOSep 17Option Exercise0.6718,01212,06862,773Sep 21 06:00 PM
Evans John M.CEOAug 19Option Exercise1.0312,00012,3601,033,525Aug 20 06:05 PM
Evans John M.CEOAug 19Sale99.4920,0001,989,744203,000Aug 20 06:05 PM
Evans John M.CEOJul 07Option Exercise1.0325,00025,7501,046,525Jul 08 06:00 PM
Evans John M.CEOJul 07Sale107.8725,0002,696,8261,021,525Jul 08 06:00 PM
COOPER GRAHAM KDirectorJul 06Option Exercise17.002,61444,4382,614Jul 08 06:00 PM
COOPER GRAHAM KDirectorJul 06Sale120.612,614315,2630Jul 08 06:00 PM
Burrell Terry-AnnCFOJun 30Option Exercise13.6830,000410,40054,809Jul 02 06:01 PM
Burrell Terry-AnnCFOJun 30Sale122.0030,0003,660,00024,809Jul 02 06:01 PM
COOPER GRAHAM KDirectorJun 28Option Exercise17.0012,045204,76512,045Jun 30 06:00 PM
Burrell Terry-AnnCFOJun 28Option Exercise13.6845,000615,60069,809Jun 30 06:00 PM
Ciaramella GiuseppePresident & CSOJun 28Option Exercise17.0078,5801,335,860123,341Jun 30 06:00 PM
Ciaramella GiuseppePresident & CSOJun 28Sale107.3578,5808,435,36544,761Jun 30 06:00 PM
Burrell Terry-AnnCFOJun 28Sale107.6945,0004,846,01624,809Jun 30 06:00 PM
COOPER GRAHAM KDirectorJun 28Sale106.3412,0451,280,8970Jun 30 06:00 PM
Evans John M.CEOApr 23Option Exercise1.036,0006,1801,021,429Apr 23 04:45 PM
Evans John M.CEOApr 21Sale70.4925,0001,762,2161,015,429Apr 23 04:45 PM
Ciaramella GiuseppePresident & CSOMar 05Option Exercise0.674,0302,70019,761Apr 02 05:13 PM
Burrell Terry-AnnCFOJan 04Option Exercise13.6825,000342,00032,309Jan 05 05:40 PM
Burrell Terry-AnnCFOJan 04Sale81.7825,0002,044,4857,309Jan 05 05:40 PM
Ciaramella GiuseppePresident & CSODec 30Option Exercise0.9555,84253,19747,573Jan 04 05:32 PM
Ciaramella GiuseppePresident & CSODec 30Sale83.2643,8423,650,1443,731Jan 04 05:32 PM
Evans John M.CEODec 30Sale84.9422,3001,894,125970,957Jan 04 05:31 PM